Vertex Pharmaceuticals Inc (NASDAQ: VRTX). Extremely significant negative changes in investment behavior have recently occurred: negative upside/downside volume developed, and its shorter term price trend turned down.
Vertex Pharmaceuticals Inc (NASDAQ: VRTX). Important negative changes in fundamentals have recently occurred: the consensus estimate for December, 2024 decreased significantly, and significant quarterly earnings deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of B. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, VRTX is expected to continue to be an important Value Builder.
Vertex Pharmaceuticals has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Vertex Pharmaceuticals has a neutral Appreciation Score of 47 but a good Power Rating of 77, producing the Positive Value Trend Rating.
Recent Price Action
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) stock rose slightly by 0.1% on 8/15/24. The stock closed at $472.00. This advance was accompanied by normal trading volume. The stock has been exceptionally strong relative to the market over the last nine months and has risen 1.3% during the last week.
Be the first to comment